Longitudinal Study of Mitochondrial Hepatopathies

Status Suspended

Clinical Trial Summary

The specific aims of this study are (1) to determine the clinical phenotypes and natural history of hepatic RC and FAO disorders, (2) to determine the correlation between genotype and phenotype, (3) to determine if circulating biomarkers reflect diagnosis and predict liver disease progression and survival with the native liver, (4) to determine the clinical outcome of these disorders following liver transplantation, and (5) to develop a repository of serum, plasma, urine, tissue and DNA specimens that will be used in ancillary studies. To accomplish these aims, the ChiLDREN investigators at clinical sites (currently 15 sites) will prospectively collect defined data and specimens in a uniform fashion at fixed intervals in a relatively large number of subjects. Clinical information and DNA samples to be collected from subjects and their parents will enhance the potential for meaningful research in these disorders. A biobank of subject specimens and DNA samples will be established for use in ancillary studies to be performed in addition to this study.

Clinical Trial Description

This study will be conducted as part of the NIH-supported Childhood Liver Disease Research and Education Network (ChiLDREN). ChiLDREN is investigating rare cholestatic liver diseases of childhood: alpha-1 antitrypsin deficiency (A1AT), Alagille's Syndrome (AGS), progressive familial intrahepatic cholestasis (PFIC), bile acid synthesis defects and mitochondrial hepatopathies (all previously studied by the Cholestatic Liver Disease Consortium [CLiC]); biliary atresia (previously studied by the Biliary Atresia Research Consortium [BARC]); neonatal hepatitis; and cystic fibrosis liver disease, which is studied by a new branch of ChiLDREN known as the Cystic Fibrosis Liver Disease (CFLD) Network. In this protocol, mitochondrial hepatopathies in children and young adults will be investigated. The focus will be on respiratory chain defects (RC) and defects of fatty acid oxidation (FAO). There is little known about the full spectrum of severity and long-term natural history of mitochondrial hepatopathies. Moreover, these disorders have not been subject to prospective, rigorous clinicopathological scrutiny. ;

Study Design

Related Conditions & MeSH terms

Acute Liver Failure
Disorder of Fatty Acid Oxidation
End Stage Liver Disease
Hepatic Insufficiency
Liver Diseases
Liver Failure
Liver Failure, Acute
Mitochondrial Diseases
Respiratory Chain Deficiencies, Mitochondrial

Clinical Trial Details

NCT number	NCT01148550
Study type	Observational
Source	Arbor Research Collaborative for Health
Contact
Status	Suspended
Phase
Start date	August 18, 2010
Completion date	May 2029

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03557086` - A Randomized Controlled Trial of an Advanced Care Planning Video Decision Support Tool for Patients With End-Stage Liver Disease	N/A
Completed	`NCT04604860` - Use of EL-FIT App to Promote Physical Activity	N/A
Completed	`NCT01933789` - Improving Communication About Serious Illness	N/A
Recruiting	`NCT01724697` - Safety and Efficacy of Human Bone Marrow Stem Cells for Treatment of HBV-related Liver Cirrhosis	Phase 1/Phase 2
Recruiting	`NCT01728727` - Safety and Efficacy of Human Umbilical Cord Derived Mesenchymal Stem Cells for Treatment of HBV-related Liver Cirrhosis	Phase 1/Phase 2
Recruiting	`NCT01728688` - Safety and Efficacy of Human Autologous Peripheral Blood Stem Cells for Treatment of HBV-related Liver Cirrhosis	Phase 1/Phase 2
Not yet recruiting	`NCT01412593` - Intra-hepatic Artery Bone Marrow Derived Stem Cells Infusion for the Treatment of Advanced Liver Cirrhosis	Phase 1/Phase 2
Completed	`NCT00374582` - End Stage Liver Disease and Body Composition Assessment: Utilizing Bioelectric Impedance Analysis (BIA)	N/A
Completed	`NCT00249652` - Transplant and Addiction Project (TAP) - 1	Phase 1/Phase 2
Recruiting	`NCT05998330` - LiverPAL: A Trial of Inpatient Palliative Care for Patients With Advanced Liver Disease	N/A
Completed	`NCT04546048` - The Early Strength Training Program in Post-transplant Liver Cases	N/A
Active, not recruiting	`NCT03580629` - Pilot Study of the Liver Live Donor Champion Program	N/A
Recruiting	`NCT04037995` - Real World Study of End-stage Liver Disease in China
Recruiting	`NCT03870568` - Functional Assessment in Liver Transplantation
Recruiting	`NCT03633812` - Effect of Preoperative Beta Blocker Use Postoperative Renal Function in the Patients Undergoing Liver Transplantation
Active, not recruiting	`NCT02889094` - French HIV-HBV Cohort
Completed	`NCT02444273` - The Feasibility of a Prehabilitation Program in the Liver Transplant Population at Barnes-Jewish Hospital	N/A
Recruiting	`NCT01711073` - Mobilization of Stem Cells With G-CSF and Mozobil in Patients With End Stage Liver Disease	Phase 1
Not yet recruiting	`NCT06069050` - SALT in Adolescents With End-stage Liver Disease	N/A
Recruiting	`NCT03228290` - Functional Assessment in Liver Transplantation

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Longitudinal Study of Mitochondrial Hepatopathies — MITOHEP

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms